Mechanisms of Precise Immune Cell Phenotyping and Prognostic Prediction in Severe Infection

ConditionSepsis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSecond Affiliated Hospital of Wenzhou Medical University

About this trial

The goal of this observational study is to learn how changes in immune cells are linked to outcomes in adults with severe infection who are treated in the intensive care unit (ICU). Severe infections, including sepsis, can affect how the immune system works and may lead to poor recovery or death. Researchers want to better understand these immune changes so that people at higher risk can be identified earlier.

The main questions this study aims to answer are:

Are certain immune cell patterns linked to survival or death within 28 days? Are these immune patterns linked to organ failure or longer stays in the ICU? Participants will be adults with severe infection who are admitted to the ICU as part of their routine medical care. This study does not change or add to their medical treatment.

Participants will:

Have small blood samples collected at several time points during their ICU stay Allow researchers to review their medical records, including test results and outcomes Researchers will analyze immune cells in the blood and relate these findings to clinical outcomes. The results may help improve future risk assessment and understanding of immune changes in people with severe infection.

Eligibility criteria

Qualifiers

Adults aged 18 years or older

Admission to the intensive care unit (ICU)

Diagnosis of severe infection, including sepsis, based on established clinical criteria

Enrollment within the early phase of ICU admission

Disqualifiers

Age younger than 18 years

Pregnancy or breastfeeding

Known history of hematologic malignancy or active solid malignancy receiving chemotherapy

Known primary immunodeficiency or long-term immunosuppressive therapy prior to ICU admission

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

200 Participants
are grouped into 1 trial group

Locations

This trial has no locations